AI-designed, gene-specific, delivery-ready nucleases and gene-editing therapies using a platform that integrates generative protein models with synthetic biology. Editors optimized for enhanced specificity, efficiency and compact size; lead program targets LRRK2 to halt Parkinson’s disease progression and enable treatments across thousands of genetic disorders.